Epigenomics, J&J Pharmaceutical form research, development agreement

By Elaine Rigoli

Tampa, Fla., Aug. 7 - Epigenomics AG and Johnson & Johnson Pharmaceutical Research & Development, LLC have entered into a research and development collaboration to identify and analyze potential biomarkers for use in Johnson & Johnson's oncology program.

Epigenomics said it will use its proprietary differential methylation hybridization (DMH) chip technology to discover biomarkers that may support the development of oncology compounds.

DNA methylation is a biological process responsible for controlling genetic activity that occurs in distinct patterns in cells, and this chip allows for rapid profiling of methylation patterns across the entire genome. Changes in these patterns can act as a marker for diseases such as cancer and for predicting response to drug treatment.

Under the agreement, Epigenomics will receive an undisclosed upfront payment. Further financial details were not disclosed.

Based in Berlin, Germany, Epigenomics is a molecular diagnostic company.

Johnson & Johnson Pharmaceutical performs research and development work for the pharmaceutical business units of Johnson & Johnson worldwide and is located in Raritan, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.